

Attorney Docket No.: 601-1-077DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Peter Lobel, et al.

SERIAL NO.: 10/643,233

EXAMINER: Anoop Singh., Ph.D.

DATE FILED: August 18, 2003


ART UNIT: 1632

FOR: NOVEL HUMAN LYSOSOMAL PROTEIN AND METHODS OF ITS
USE

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on August 3, 2006.

Carolyn Di Meglio
(Name of Depositor)


(Signature and Date)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Supplemental Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.


Enclosed please find copies of References AH through AN listed on the attached Supplemental Form PTO-1449. Enclosed please find check in the amount of \$180.00 in payment of this filing. However, should the Patent and Trademark Office determine additional fees are due, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

08/08/2006 HDESTA1 0000008 10643233

02 FC:1806


180.00 OP

Respectfully submitted,


Sarah J. Fashena, Ph.D.
Agent for Applicants
Registration No. 57,600

KLAUBER & JACKSON LLC
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800

Date: August 3, 2006



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	601-1-077DIV1
		SERIAL NO.	10/643,233
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Supplemental Information Disclosure Statement)		APPLICANT	Peter Lobel, et al.
		FILING DATE	August 18, 2003
		GROUP	1632

U.S. PATENT DOCUMENTS

EXAMINE R INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AH	B. L. Davidson, et al., Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system, Proc. Natl. Acad. Sci., 97:3428-3432 (2000)
AI	X. Xiao, et al., Gene transfer by adeno-associated virus vectors into the central nervous system, Exp. Neurol, 144:113-24 (1997) Abstract
AJ	K.R. Clark, et al., Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression, J Drug Target, 7:269-83 (1999) Abstract
AK	M.A. Passini, et al., Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis, The Journal of Neuroscience, 26:1334-1342 (2006)
AL	D. Sondhi, et al., AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-1 expression compatible with therapy for LINCL, Gene Therapy, 12:1618-1632 (2005)
AM	R.E. Haskell, et al., Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-1 to the mouse central nervous system, Gene Therapy, 10:34-42 (2003)
AN	N.R. Hackett, et al., Safety of direct administration of AAV2 _{cu} hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates, Human Gene Therapy, 16:1484-1503 (2005)

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.